JPWO2021178707A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021178707A5
JPWO2021178707A5 JP2022552651A JP2022552651A JPWO2021178707A5 JP WO2021178707 A5 JPWO2021178707 A5 JP WO2021178707A5 JP 2022552651 A JP2022552651 A JP 2022552651A JP 2022552651 A JP2022552651 A JP 2022552651A JP WO2021178707 A5 JPWO2021178707 A5 JP WO2021178707A5
Authority
JP
Japan
Prior art keywords
deficiency
nucleic acid
seq
acid sequence
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022552651A
Other languages
English (en)
Japanese (ja)
Other versions
JP7817176B2 (ja
JP2023515692A (ja
JP2023515692A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/020929 external-priority patent/WO2021178707A1/en
Publication of JP2023515692A publication Critical patent/JP2023515692A/ja
Publication of JPWO2021178707A5 publication Critical patent/JPWO2021178707A5/ja
Publication of JP2023515692A5 publication Critical patent/JP2023515692A5/ja
Application granted granted Critical
Publication of JP7817176B2 publication Critical patent/JP7817176B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022552651A 2020-03-04 2021-03-04 代謝性肝障害の治療のための組成物と方法 Active JP7817176B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062985047P 2020-03-04 2020-03-04
US62/985,047 2020-03-04
US202063121488P 2020-12-04 2020-12-04
US63/121,488 2020-12-04
PCT/US2021/020929 WO2021178707A1 (en) 2020-03-04 2021-03-04 Compositions and methods for the treatment of metabolic liver disorders

Publications (4)

Publication Number Publication Date
JP2023515692A JP2023515692A (ja) 2023-04-13
JPWO2021178707A5 true JPWO2021178707A5 (https=) 2024-03-12
JP2023515692A5 JP2023515692A5 (https=) 2024-03-12
JP7817176B2 JP7817176B2 (ja) 2026-02-18

Family

ID=75267602

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022552651A Active JP7817176B2 (ja) 2020-03-04 2021-03-04 代謝性肝障害の治療のための組成物と方法

Country Status (8)

Country Link
US (1) US12540335B2 (https=)
EP (1) EP4114469A1 (https=)
JP (1) JP7817176B2 (https=)
KR (1) KR20220149588A (https=)
CN (1) CN115515646A (https=)
AU (1) AU2021230361A1 (https=)
CA (1) CA3169529A1 (https=)
WO (1) WO2021178707A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022061002A1 (en) * 2020-09-18 2022-03-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency
CA3094859A1 (en) * 2020-10-01 2022-04-01 Entos Pharmaceuticals Inc. Proteolipid vesicles formulated with fusion associated small transmembrane proteins
WO2022187671A1 (en) * 2021-03-04 2022-09-09 Poseida Therapeutics, Inc. Compositions and methods for the treatment of hemophilia
GB202205606D0 (en) * 2022-04-14 2022-06-01 Genespire S R L Lentiviral vector
AU2024224841A1 (en) * 2023-02-21 2025-08-21 Poseida Therapeutics, Inc. Aav piggybac transposon polynucleotide compositions and methods of use therefor
KR20250173518A (ko) * 2023-04-05 2025-12-10 포세이다 테라퓨틱스, 인크. 트랜스포사제 폴리뉴클레오티드 및 그의 용도
IL325133A (en) * 2023-06-07 2026-02-01 Res Inst Nationwide Childrens Hospital Gene therapy for lysosomal acid lipase deficiency (LAL-D)
WO2025171163A1 (en) * 2024-02-06 2025-08-14 Duke University Compositions for and methods of treating lysosomal storage diseases

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4309989A (en) 1976-02-09 1982-01-12 The Curators Of The University Of Missouri Topical application of medication by ultrasound with coupling agent
FR2374910A1 (fr) 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4766067A (en) 1985-05-31 1988-08-23 President And Fellows Of Harvard College Gene amplification
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
EP0545913B1 (en) 1986-08-18 1999-02-24 Emisphere Technologies, Inc. Delivery systems for pharmacological agents
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US4921794A (en) 1987-01-14 1990-05-01 President And Fellows Of Harvard College T7 DNA polymerase
US4795699A (en) 1987-01-14 1989-01-03 President And Fellows Of Harvard College T7 DNA polymerase
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5091310A (en) 1988-09-23 1992-02-25 Cetus Corporation Structure-independent dna amplification by the polymerase chain reaction
US5066584A (en) 1988-09-23 1991-11-19 Cetus Corporation Methods for generating single stranded dna by the polymerase chain reaction
US5142033A (en) 1988-09-23 1992-08-25 Hoffmann-La Roche Inc. Structure-independent DNA amplification by the polymerase chain reaction
US4994370A (en) 1989-01-03 1991-02-19 The United States Of America As Represented By The Department Of Health And Human Services DNA amplification technique
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5580734A (en) 1990-07-13 1996-12-03 Transkaryotic Therapies, Inc. Method of producing a physical map contigous DNA sequences
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5643252A (en) 1992-10-28 1997-07-01 Venisect, Inc. Laser perforator
US5849695A (en) 1993-01-13 1998-12-15 The Regents Of The University Of California Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals
CZ206195A3 (en) 1993-02-12 1996-04-17 Univ Leland Stanford Junior Controlled transcription of target genes and other biological materials
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US6218185B1 (en) 1996-04-19 2001-04-17 The United States Of America As Represented By The Secretary Of Agriculture Piggybac transposon-based genetic transformation system for insects
US5827729A (en) 1996-04-23 1998-10-27 Advanced Tissue Sciences Diffusion gradient bioreactor and extracorporeal liver device using a three-dimensional liver tissue
US5879681A (en) 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion A system for administering drugs through the skin
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6962810B2 (en) 2000-10-31 2005-11-08 University Of Notre Dame Du Lac Methods and compositions for transposition using minimal segments of the eukaryotic transformation vector piggyBac
EP2160461B1 (en) 2007-07-04 2012-08-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Hyperactive variants of the transposase protein of the transposon system sleeping beauty
WO2010099296A1 (en) 2009-02-26 2010-09-02 Transposagen Biopharmaceuticals, Inc. Hyperactive piggybac transposases
US20120156170A1 (en) * 2009-08-31 2012-06-21 Tadashi Tanabe Drug composition for angiogenesis therapy
US20130023033A1 (en) 2010-03-29 2013-01-24 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
WO2012050919A2 (en) * 2010-09-28 2012-04-19 The University Of Notre Dame Chimeric spider silk and uses thereof
WO2012074758A1 (en) * 2010-11-16 2012-06-07 Transposagen Bioharmaceuticals, Inc. Hyperactive piggybac transposases
AU2013281328B2 (en) * 2012-06-27 2017-11-23 MeiraGTx Gene Regulation Limited Combination for treating an inflammatory disorder
WO2014143884A2 (en) 2013-03-15 2014-09-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic methylmalonyl-coa mutase transgene for the treatment of mut class methylmalonic acidemia (mma)
RS60902B1 (sr) 2014-03-09 2020-11-30 Univ Pennsylvania Kompozicije korisne u lečenju nedostatka ornitinske transkarbamilaze (otc)
CA2943296C (en) * 2014-03-21 2022-10-18 The Sydney Children's Hospitals Network (Randwick And Westmead) (Incorporating The Royal Alexandra Hospital For Children) Stable gene transfer to proliferating cells
US10927384B2 (en) 2014-04-09 2021-02-23 Dna Twopointo Inc. DNA vectors, transposons and transposases for eukaryotic genome modification
KR20180034467A (ko) 2015-08-03 2018-04-04 마이오도파 리미티드 L-dopa의 전신 합성 및 조절
US20170112108A1 (en) * 2015-10-22 2017-04-27 Hera Testing Laboratories, Inc. Genetically modified non-human mammals having modified liver cells and/or tissue and methods of making same
WO2017099838A1 (en) 2015-12-11 2017-06-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gene therapy for combined methylmalonic acidemia/aciduria and hyperhomocysteinemia/homocystinuria, cobalamin c type, and deficiency of mmachc
EP3680280A4 (en) 2017-09-05 2021-06-02 Toray Industries, Inc. FIBER REINFORCED THERMOPLASTIC RESIN MOLDINGS
KR102849343B1 (ko) * 2018-03-07 2025-08-25 포세이다 테라퓨틱스, 인크. Cartyrin 조성물 및 사용 방법
EP3847197A1 (en) 2018-09-05 2021-07-14 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use

Similar Documents

Publication Publication Date Title
JP2024009857A5 (https=)
JP2020019772A5 (https=)
JP2020519284A5 (https=)
JP2020500541A5 (https=)
JP2017535266A5 (https=)
JP2021523702A5 (https=)
JP2021512649A5 (https=)
IL292999A (en) Compositions and methods of treating amyotrophic lateral sclerosis (als)
JP2017509632A5 (https=)
JP2020522269A5 (https=)
JP2024099770A5 (https=)
JP2021522173A5 (https=)
JP2020535803A5 (https=)
IL273394B1 (en) Variant rnai
JPWO2021178707A5 (https=)
JPWO2021067448A5 (https=)
JP2023059858A5 (https=)
JPWO2020214613A5 (https=)
JPWO2020214609A5 (https=)
JPWO2021053222A5 (https=)
JPWO2019204593A5 (https=)
JPWO2020168222A5 (https=)
JPWO2020028816A5 (https=)
CN118291541B (zh) 一种诱导型启动子
JPWO2019213668A5 (https=)